RU2488384C2 - Композиции для лечения неопластических заболеваний - Google Patents

Композиции для лечения неопластических заболеваний Download PDF

Info

Publication number
RU2488384C2
RU2488384C2 RU2010110658/15A RU2010110658A RU2488384C2 RU 2488384 C2 RU2488384 C2 RU 2488384C2 RU 2010110658/15 A RU2010110658/15 A RU 2010110658/15A RU 2010110658 A RU2010110658 A RU 2010110658A RU 2488384 C2 RU2488384 C2 RU 2488384C2
Authority
RU
Russia
Prior art keywords
composition according
taxane
weight
carrier
pvp
Prior art date
Application number
RU2010110658/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010110658A (ru
Inventor
Якоб Хендрик БЕЙНЕН
Йоханнес Хенрикус Маттиас СХЕЛЛЕНС
Йоханнес МУС
Бастиан НЁЙЕН
Original Assignee
Стихтинг Хет Недерландс Канкер Институт
Слотерварт Партисипатис Бв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стихтинг Хет Недерландс Канкер Институт, Слотерварт Партисипатис Бв filed Critical Стихтинг Хет Недерландс Канкер Институт
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Publication of RU2010110658A publication Critical patent/RU2010110658A/ru
Application granted granted Critical
Publication of RU2488384C2 publication Critical patent/RU2488384C2/ru

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010110658/15A 2007-08-24 2008-08-22 Композиции для лечения неопластических заболеваний RU2488384C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
GB0716591.3 2007-08-24
US60/957,764 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (2)

Publication Number Publication Date
RU2010110658A RU2010110658A (ru) 2011-09-27
RU2488384C2 true RU2488384C2 (ru) 2013-07-27

Family

ID=38599259

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010110658/15A RU2488384C2 (ru) 2007-08-24 2008-08-22 Композиции для лечения неопластических заболеваний

Country Status (5)

Country Link
JP (1) JP5404625B2 (cg-RX-API-DMAC7.html)
CN (1) CN101854919B (cg-RX-API-DMAC7.html)
ES (1) ES2535401T3 (cg-RX-API-DMAC7.html)
GB (1) GB0716591D0 (cg-RX-API-DMAC7.html)
RU (1) RU2488384C2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂
CN118948828A (zh) 2017-03-15 2024-11-15 Dfb索里亚有限责任公司 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法
WO2019047812A1 (zh) 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
MX2021007480A (es) * 2018-12-21 2021-10-13 Modra Pharmaceuticals B V Tratamiento de combinación para tumores sólidos utilizando docetaxel y un inhibidor de cyp3a.
ES3026709T3 (en) * 2018-12-21 2025-06-12 Modra Pharmaceuticals B V Cancer treatment using docetaxel by controlling peak plasma levels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
WO2004050058A2 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371836C (en) * 1999-05-27 2006-01-31 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012714A1 (en) * 2002-08-05 2004-02-12 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
WO2004050058A2 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEZOE T. «HIV-1 protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo» // Cancer Research, 2004, p.7426-74316164 [онлайн]. [Найдено в Интернет 03.05.2012] <URL:http://www.ncbi.nlm.nih.gov/pubmed/15492266>. BARDELMEIJER H.A. «Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted be rotonavir» // Cancer Research, 2002, p.6158-6164 [онлайн]. [Найдено в Интернет 03.05.2012] <URL:http://www.ncbi.nlm.nih.gov/pubmed/12414642 >. *

Also Published As

Publication number Publication date
GB0716591D0 (en) 2007-10-03
CN101854919B (zh) 2012-02-15
JP5404625B2 (ja) 2014-02-05
JP2010536837A (ja) 2010-12-02
CN101854919A (zh) 2010-10-06
RU2010110658A (ru) 2011-09-27
ES2535401T3 (es) 2015-05-11
BRPI0816144A2 (pt) 2015-02-18

Similar Documents

Publication Publication Date Title
RU2488384C2 (ru) Композиции для лечения неопластических заболеваний
ES2399810T3 (es) Forma de dosificación farmacéutica sólida que comprende una dispersión sólida de ritonavir y lopinavir
ES2409055T3 (es) Sistema de suministro de fármacos que comprende polioxazolina y un agente bioactivo
US10632074B2 (en) Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product
RU2435592C2 (ru) Композиция пролекарства для борьбы с вирусом гепатита с
US8053000B2 (en) Compositions for drug delivery
KR20160093611A (ko) 경구 투여를 위한 약물 제제의 제조 방법
ES2894112T3 (es) Nanopartículas que contienen tacrolimus
CA2976811A1 (en) Solid dispersions of ospemifene
WO2015093452A1 (ja) マイクロニードル
RU2018109496A (ru) Фармацевтическая композиция, содержащая электрогидродинамически полученные волокна, композиция, имеющая улучшенное время удержания в месте применения
CN104352482A (zh) 膜组合物
Kumari et al. Paramount role of solid dispersion in enhancement of solubility
WO2015030854A1 (en) Solid dispersion formulation of an antiviral compound
JP2019519570A5 (cg-RX-API-DMAC7.html)
JP2010536837A5 (cg-RX-API-DMAC7.html)
JP2019524724A (ja) テコビリマットの経口用医薬組成物及びその調製法
KR101478779B1 (ko) 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
CN101827584A (zh) N-芳基脲基药物的固态分散体产品
WO2014041489A2 (en) Pharmaceutical dosage form
JP2012500788A5 (cg-RX-API-DMAC7.html)
CA2878689A1 (en) Crystalline forms of an hcv inhibitor
JP7733160B2 (ja) カンナビジオール懸濁液を含有する可溶性マイクロニードル及びその調製方法
Mogoşanu et al. Pharmaceutical natural polymers: structure and chemistry